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      Metabolomics studies provide useful information about health and disease status. Metabolite based 
investigations on various cancers is a powerful approach to diagnosis, prognosis and therapy of cancer 
diseases. Recently by using advanced analytical techniques such as NMR and MS and its hyphenation 
methods, global metabolic profiling of diseases has been possible. It is predictable that international 
contributions and software developments in the future will lead to accurate instrumental analysis based on  a 
large number of  human samples that finally will improve validation methods and reach this field from the 
research phase to the clinical phase. In this review, we also discussed the latest developments in analytical 
methods, application of data analysis, investigation of useful databases and the curent application of 
metabolomics in cancer diseases that have led to the identification of related biomarkers. In continuation, we 
listed biomarkers involved in cancer diseases that have been published during recent years. 
 
Keywords: Metabolomics; Biomarker; Cancer; Database. 
 
Abbreviations: NMR: Nuclear Magnetic Resonance, MS: Mass Spectrometry, HMDB: Human 
Metabolome Database, RF: radio frequency ; EBC: Exhaled breath condensate ; CSF: cerebro-spinal fluid; 
AF: Amniotic fluid; JRES: J-resolved ; CPMG: Carr-Purcell-Meiboom-Gill ; TMS: Trimethylsilan ; TSP: 3-
trimethyl silyl propionic acid; DSS:  2, 2-dimethyl-2-sila pentane-5-sulfonate sodium salt ; MAS-NMR: 
magic angle spinning Nuclear Magnetic Resonance; HR-MAS: High Resolution Magic Angle Spinning ; 
GC-MS: Gas chromatography-mass spectrometry; EI:  electron impact; CI: chemical ionization ; MSTFA: 
N-methyl-trimethyl silyltriflouroacetamide ;GC-TOF-MS: Gas chromatography time of flight -mass 
spectrometry; LC-MS: Liquid chromatography mass spectrometry; RP-HPLC: reversed phase high 
performance liquid chromatography; ESI:  electrospray ionization; MALDI: Matrix Assisted laser 
desorption/ionization ; DESI: Desorption electrospray ionization Mass Spectrometry; EESI: Extractive 
electrospray ionization ; UHPLC: Ultra high-performance liquid chromatography CE-MS: Capillary 
Electrophorese-mass spectrometry; MVA: Multivariate analysis; PCA: principle component analysis ; PCs: 
principal components; STOCSY : statistical correlation spectroscopy; CLASSY: cluster analysis statistical 
spectroscopy; PLS: partial least square ; DFA: discriminant function analysis ; PCR: Principal Component 
Regression ;PLS-DA:  partial least square discriminant analysis; OPLS: Orthogonal partial least square; 
ANN: Artificial neural network ; ROC: receiver-operator characteristic ; OSCC: Oral squamous cell 
carcinoma ; HNSCC: Head and neck squamous cell carcinoma ; lysoPCs: Lysophosphatidylcholines . 
 
INTRODUCTION  
   In the past few years, great changes have taken 
place in the biological sciences leading into the 
emergence field of systems biology. The 
metabolomics and metabonomics terms were used 
in the late nineteenth and early twentieth-century  
[1, 2]. Metabolomics is one of the important 
building blocks of systems biology, 
complementary of other “omic” sciences and the 
closest correlation to phenotype. On the other 
hand, metabolites are the reflection of 
physiological and disease status, then study of 
 




metabolites facilitates understanding biochemical 
pathways. Metabolome is the collection of small 
molecules in a mass below approximately 1500 
Dalton (metabolites) that  produced by a cell as a 
result of response to environmental stresses[3] .
Metabonomics were defined by Nicolson as 
“quantitative measurement of dynamic multi 
parametric metabolic response of living systems 
to pathophysiological stimuli or genetic 
modification”[4]. Metabolomics were defined as 
“study of the complete set of metabolites/low 
molecular intermediate, which are contexts 
dependent, varying according to the 
physiological, developmental or pathological state 
of cell, tissue and organ or organism” [3]. These 
two terminologies often use instead of each other.  
Metabolites are divided into two categories; 
Endogenous and Exogenous. Endogenous 
metabolites, are the collection of chemicals that 
produce and consume by organism in the absence 
of extracellular materials and exogenous 
metabolites are foreign substances such as 
nutrients, drugs, xenobiotic and environmental 
change [5]. 
Analysis of metabolism has different ways; target 
analysis and integrated analysis. Target analysis 
deals with the measurement of specific 
metabolites or focuses on one or more metabolic 
pathways. [6]. Untargeted analysis is 
simultaneous measurement of metabolites without 
bias It must be noted that untargeted 
metabolomics somewhere refer metabolic 
profiling  [7]. Untargeted analysis has two 
subsets: metabolic fingerprinting and metabolic 
footprinting. Metabolic Fingerprinting is a 
measurement of collection of metabolites without 
any previous assumption  [8], although it is 
impossible to evaluate all present metabolites, but 
with recent advances in analytical instruments and 
Chemometric techniques can be closer to this 
goal. Metabolic Footprinting is defined as 
laboratory culture media that measurement of 
changes that caused by an organism. Another 
definition of Metabolic Footprinting is secreted 
metabolites that caused by an organism and often 
apply in biotechnology and microbiology  [9]. 
 
General workflow of metabolic studies can be 
categorized into five steps: 1) Sample preparation 
2) Analytical platforms based on NMR or MS 
spectroscopy, 3) pre-processing 4) data analysis 
(via Chemometrics methods) and 5) metabolite 
identification and data interpretation  
 
Biological samples 
      Metabolites are generated by the processes of 
metabolism in cells, tissue or organ. The human 
body contains approximately 38000 (exactly 
37,166, until now, according to a very recent 
report on the HMDB Version 3.6) detectable 
metabolites that are very diverse chemical 
compounds such as volatile, polar and more polar 
metabolites (Table 1) 
  
Table 1. classes of chemical compounds 












Aldehydes, Ketones Hydrophilic 
Carbohydrate 
Nucleosides 














Because of difference in polarity of compounds, it 
is impossible to measure all of metabolites with a 
unique technics. Factors that affecting 
metabolomics analysis is gender [10], age [10], 
lifestyle [10], smoky [11]and physical activity 
[12]. One of the most important steps in metabolic 
approach is the selection of the sample and its 
preparation before instrumental analysis. The 
required analytical technique varies depending on 
types of sample. The common samples for 
metabolic analysis are blood (serum/plasma) [15], 
urine, , saliva, tissue, cell line [13], exhaled 
cerebro-spinal fluid(CSF) breath and amniotic 
fluids [14, 15]. Each of these samples has 
advantages and limitations of the analysis that 










     A variety of analytical technologies have been 
applied to metabolomics studies. The most 
common analytical instrument that have been 
employed are nuclear magnetic resonance (NMR) 
spectroscopy and hyphenated mass spectrometry 
[16]. At first, a brief explanation is given and then 
their application in the diagnosis of cancer will be 
discussed. 
Metabolomics based on NMR spectroscopy 
      NMR spectroscopy is application of strong 
magnetic fields and radio frequency (RF) pulses 
to the nuclei of atoms for atoms either an odd 
atomic number (e.g., 
1
H) or odd mass number  
(e.g., 13C, 31P) or both of them (e.g. 14N) in the 
presence of a strong magnetic field, the nucleus 
will cause the possess spin (nuclear spin). 
Absorption of RF energy will then allow the 
nuclei to be promoted from low-energy to high-
energy spin states, and the subsequent emission of 
radiation during the relaxation process is detected. 
The majority of applications employs 1H (proton) 
NMR for clinical studies and as the known 
metabolites contain various hydrogen atoms in 
their molecular structure [17]. Between used 
techniques; The NMR has attracted so much 
attention to itself because it is rapid, Quantitative, 
non-destructive and cost effective. It needs little 
or no sample preparation and produces repeatable 
and reproducible results. NMR is a powerful tool 
for assigning and identification in a large  number 
of metabolites in complex biofluids because each 
metabolite has its chemical shifts and unique 
multiple patterns. [18]. 
 
 
This technique has some limitations, for example, 
low sensitivity (in comparison with MS 
spectroscopy) and signal overlapping. It must be 
noted that NMR sensitivity depends on some 
factors such as natural abundance of the atom that 
are studied (1H, 31P, 19F 100%; 13C1. 10%; 15N 
0.37%).This limitation was improved by the 
construction of modern NMR instruments with 
higher magnetic fields and special microprobes 
for trace analysis. By using high magnetic fields 
(800-900 MHz) and cryogenic probe signal to 
noise were Improve dramatically [19]. 
Another approach is the use of microbes instead 
of conventional 5 mm probes, new probes have a 
diameter of 1-3 mm or micro scaled [20]. This 
also will reduce the sample amount that is needed 
for analysis (600µl to 60µl respectively).  
Recently, two dimensional (2D) homonuclear 1H, 
J-resolved (JRES) nuclear magnetic resonance 
spectroscopy is used in metabolomics research. 
This NMR method contains many advantages 
such as disperses the overlapping resonances into 
a second dimension, reducing overlap, simplify 
spectral assignments and accurate quantification 
.[12]  One of the challenges in NMR-based 
metabolomics is suppression of water in biofluids. 
This problem has been solved by applying pulse 
sequences of  standard pulse sequence nuclear 
Overhauser effect spectroscopy (NOESY preset) 
[22]. This pulse program has been used especially 
for urine samples. Another challenge in NMR-
based approach is signal's suppression of 
macromolecules that is possible by Carr-Purcell-
Meiboom-Gill (CPMG) sequence  [23, 24]. 
 
Table2. common biological samples in metabolic studies 







-Are common biofluids in NMR metabolomics 
-Easy to obtain 
-Most of the relevant NMR detectable 
metabolites have been by (HMDB) 
-non-invasive 






-Easy to collection and storage 
-Easy sample preparation 
-Good for toxicology or drug follow-up studies 
-Urine contains more metabolites than blood and 
CSF. 
-More overlapping signals in an NMR 
spectrum 
-Need to maintain homeostasis results in 













- Tissue is even greater homeostasis regulation 
than plasma and urine therefore provide highly 
consistent metabolic measurements 
-Are suitable for the study of  specific sites for 
body (toxicity) 
-Need HR-MAS 
-More difficult to collect 
-Invasive 














- Exhaled breath condensate (EBC) collection is 
an innovative method 
-Rich in volatile metabolites (such as aldehydes, 
ketones, alcohols, hydrocarbons and esters) 
-Inexpensive 
-Safe and noninvasive method of diagnostic and 
therapeutic monitoring 
- Limited to the investigation of 
respiratory disease 
-  Dilution is an issue that is a problem 
with all methods of sampling the airway 
and lungs including sputum collection 
and bronchoalveolar lavage 
- The small volume of sample collected 
- EBC is currently used only as a 
research tool, (due to the lack of 
appropriate standardization and the 













CSF indirectly reflects the biochemical 
processes occurring in the brain. 
Therefore provides information about states of 
normal or pathological metabolism of the brain. 
-The biochemical composition of CSF contains 
metabolites which are secreted by the central 
nervous system (CNS) 
-CSF has lower protein and lipid content 
- Signal overlaps in CSF is not as serious 









Saliva encompasses the secretions of three major 
glands namely parotid gland, submandibular 
gland and sublingual gland and other minor 
salivary glands
 
It reflects a large range of physiological needs 
and information 
-Most compounds found in blood 




collection of sample is low-cost. 
Highly sensitive analysis techniques is 





Cell line Good for understanding of the in vitro and in 
vivo actions of drugs - and aid in their rapid 
incorporation into novel therapeutic settings 
-Cells can also be stored in a deep frozen state 
and doing so there is no alteration to their 
growth rate or genetic composition and they can 
be revived whenever needed 
-It is far more economical to use cell cultures 
instead of rearing animals and doing 
experiments with animals 
-There is no requirement for ethical approval 
 
-Need for specialized equipment, 
-Their sensitivity to varying 
environmental conditions, e.g. power 
failure. 
-Is that cell cultures are very prone to 
infections 








Amniotic fluid (AF) composition reflects the 
physiological status during fetal development 
and it may be used to detect potential 
pathological conditions excretions and placental 
tissues. 
AF contains large amounts of proteins 
and metabolites produced by the amnion 




Based on HMDB Version 3.6 
 





Because of the low concentration of the 
Metabolites in biofluids (serum), proteins (such as 
albumin) with high concentration, has been 
masked the NMR signals of metabolites. For 
solving this major problem in NMR, researchers 
use this item that, relaxation time (T2) of 
Metabolites relatively long then produce narrow 
peak and  in contrast, macromolecules such as 
proteins have short T2 and produce broad peaks. 
This difference in relaxation times causes a big 
background of protein in 1HNMR signals. 
Veenstra and co-workers [28] have designed 
WET–CPMG pulse sequence to remove these 
unwanted signals. In this pulse program, NMR 
peak intensities are decreased proportional to their 
T2 relaxation times. Therefore, CPMG used to 
suppress signals arising from macromolecules  
[29, 30]. Another great merit of NMR technique is 
ready to measure the concentration of metabolites 
(qNMR) because the intensity in a resonance line 
is directly proportional with the number of 
resonant nuclei (spins)[31].  
It must be noted that in order to measure exact 
concentration of metabolite it is necessary to use 
an internal standard in NMR spectroscopy. 
Trimethylsilan (TMS) is useful for organic 
solvent but common reference for biological 
samples are (3-trimethyl silyl propionic acid-d4, 
TSP-d4) and 2, 2-dimethyl-2-sila pentane-5-
sulfonate sodium salt (DSS) [32, 33]. 
One of the recent developments in NMR 
technique’s automated NMR using Autosampler 
that is applying for NMR structure determination, 
epidemiological or population screening studies. 
Automated NMR can analysis 200-300 sample 
per day  [34, 35]. High Resolution Magic Angle 
Spinning (HR-MAS) for solid samples is another 
powerful NMR technics in metabolomics. In this 
technique that  invented for the 1950s use of 
magic angle spinning NMR (MAS-NMR) allows 
intact tissues and cells to be examined with little 
sample preparation (~20 mg) or no preparation  
[36, 37]. MAS-NMR significantly reduces the 
effect of magnetic-field inhomogeneity, because a 
sample in homogeneity leads differences in 
magnetic susceptibility and causes broad and 
distorted peak shapes. HR-MAS-NMR yield's 
remarkably high-resolution spectra from a range 
of intact tissue types, therefore, provides detailed 
analysis of complex matrices such as tissue. It has 
recently been applied in toxicology and oncology, 
such as the study of the toxins- and disease-
induced changes in a variety of tissues, including 
tumors and kinds of cancers. MAS-NMR also 
provides a means to validate, and  study of 
metabolism both in vitro and in vivo conditions. 
Another advantage of HR-MAS-NMR approaches 
is usefulness in MRS imaging studies [38].  
Furthermore, HR-MAS-NMR  also has been 
applied to help interpretation of proton MRS 
imaging of tumors [39]. 
Mass based metabolomics 
    Recently, Metabolomics based on mass 
spectrometry is being used increasingly as an 
alternative approach specially hyphenated 
methods coupled with separation methods such as 
GC-MS, LC-MS, CE-MS. These techniques are 
more sensitive, selective and have wide dynamic 
range compared to NMR. The number of 
compounds that measured in mass based 
techniques strongly will depend on the resolution 
of the chromatography system and the specificity 
of the detection technique. A mass spectrometer 
can function as highly specific chromatographies. 
In this article, we have explained recent research 
results briefly based on MS detection techniques. 
Metabolomics based on GC-MS spectroscopy 
    Gas chromatography-mass spectrometry (GC-
MS) is a hyphenated technique that has been used 
over many years. This technique is suitable for 
target-metabolomics In this approach inert carrier 
gas (i.e. N2, He) moves analytes between silica 
capillary. Separation occurs as a result of 
equilibrium formed between the solutes and the 
stationary phase. Useful detectors for GC-MS are 
electron impact/ chemical ionization (EI/CI) mass 
spectrometry. Electron Impact (EI) ion source 
leads to extensive fragmentation and is helpful for  
unambiguous identification of analytes while the 
CI ion source is mild and usually uses for 
determine accurate mass measurement of 
metabolites. (Because of little fragmentation)  
GC-MS is highly sensitive, and it is suitable for 
volatile metabolites. One of the most advantages 
 




of GC-MS is access to powerful libraries such as 
NIST, Wiley Library that allows  users to search 
both chromatographies retention time and mass 
spectra of analytes. Derivatization for detection of 
some polar metabolites (for example: fatty acids, 
phenols, prostaglandins, Steroids, alkaloids, 
amino acids)  is necessary before GC-MS 
analysis.  Chemical derivatization is usually 
necessary due to decrease the polarities of 
functional groups to facilitate their separation by 
GC. Generally, there are three basic types of 
derivatization reactions: silylation, alkylation and 
acylation. Silylation is the most widespread 
derivatization method and is very suitable for 
non-volatile samples. In this respect, Silylating 
reagents react with active hydrogen and convert 
them to be silylated derivatives that are more 
volatile and thermally stable and creating narrow 
peaks. One of The most common silyating 
reagents is present N-methyl-
Ntrimethylsilyltriflouro-acetamide (MSTFA); 
Acylating reagents react with highly polar 
functional groups such as amino acids or 
carbohydrates,  and  an acyl group is attached to 
an organic compound. In this method of 
derivatization, active hydrogens (e.g., -OH, -SH 
and -NH) converted into esters, thioesters and 
amides, respectively through acylation.  One of 
Common reagent for the Acylation is 
Fluoracylimidazoles. Alkylating reagents protect 
active hydrogens and replace of active hydrogen 
by an aliphatic or aliphatic-aromatic (e.g., benzyl) 
group. Dialkylacetals are common derivatization 
reagents for the Alkylation reactions.  
GC-MS has some limitations, for example. It is 
destructive, low reproducible, low quantitation, 
needs high sample amount and  has limitations for 
the detection of more polar metabolites and 
thermally labile metabolites, one of most its 
disadvantage is incapability to identify unknown 
compounds after derivatization [40, 41]. 
Recently multidimensional GC, known GC×GC-
MS, GC-TOF-MS improved limitations of GC-
MS techniques such as resolution, sensitivity. 
GC×GC-MS has composed of two columns; the 
first column is longer than second and separates 
compounds based on volatility whereas the 
second column separates based on polarity [42]. 
LC-MS based metabolomics 
    Liquid chromatography hyphenated with mass 
spectrometry is the most important technique 
among analytical tools that has been used for 
metabolic studies. Commonly used column in  LC 
is reversed phase column (RP-HPLC), and ion 
source is  electrospray ionization (ESI) for 
detection ionic compounds and ion suppression.   
LC-MS separates, identify and quantify a very 
broad group of metabolites. It has advantages 
such as highly sensitive, no need for 
derivatization, able to analysis of thermo-labile 
metabolites, but this technique also has some 
limitations, for example, does not access to good 
libraries, thus limited structural information, has 
high matrix effects, expensive, time consuming, 
low reproducibility [43, 44]. 
In the few past years LC-MS-MS (tandem mass), 
Matrix Assisted laser desorption/ ionization 
(MALDI-MS) [45], Desorption electrospray 
ionization Mass Spectrometry (DESI) [46], 
Extractive electrospray ionization (EESI-MS) [47] 
methods have been used. These methods removed 
many problems of conventional technique (LC-
MS) for example, LC-MS-MS is suitable  to 
validate and identifying of unknown molecules 
because of the second mass analyzer [48]. 
MALDI-MS is highly sensitive, detect a wide 
range of molecules and is label free DESI and 
EESI-MS approaches are useful for high-
throughput data  [49]. 
Recently in LC-MS columns instead of 
conventional particulate have been used 
monolithic columns (for separation of peptides 
and proteins). Ultra high-performance liquid 
chromatography (UHPLC) has improved 
limitation of HPLC (chromatographic resolution, 
improved detection limit 3-5 fold) [50]. 
Recently, LC-NMR-MS has applied in 
metabolomics that it has advantages both 
techniques and has been noticed by scientists [16, 
51]. 
CE-MS 
    Capillary Electrophorese-Mass spectroscopy is 
a powerful technique for the Analysis of small 
soluble compounds in biological fluids, but it has 
not been used widely for metabolic studies. CE-
MS is useful for polar metabolites, complex 
 




biological sample that leading to high resolution, 
but this approach suffers from insufficient 
sensitivity, low reproducibility, high cost and time 
consuming. Interface of CE with MS is so 
difficult and desalting step is necessary prior to 
mass spectrometry, it has Complex methodology 
and quantification is problematic [52-54]. 
Pre- reprocessing 
    Metabolomics data are highly informative and 
extraction of them has always been a challenging 
problem. The main objective of data 
preprocessing is to convert raw spectra to datasets 
and summarize them in a table (data matrix). Both 
NMR and mass spectra contain hundreds up to 
thousand signals. Analysis of such heavy datasets 
is a more challenging process. Before stepping of 
multivariate analysis, a number of data 
pretreatments are required. The data pretreatment 
in 
1
HNMR and GC-MS are fundamentally 
different. It is for NMR data as baseline 
correction, alignment, binning, Normalization, 
scaling and transformations. Data pre-processing 
of mass peaks is one of the most challenging areas 
in the metabolomics field with regard to software 
development.  Data preprocessing for MS based 
methods are noise Filtering, data binning, Peak 
detection, Time Alignment, Missing values, 
Normalization and Scaling. Preprocessing steps 
NMR and MS based methods are summarized in 
Table 3 and Table 4 respectively: 
  




Pre-processing Explain Solution 
Baseline correction 
-Correction of distortions 
-Exclude outside 0.2-10.0ppm 
-Remove solvent water(in 4.7-5ppm) 
-Remove urea (in urine samples) 
-Automated baseline correction 
-Iterative polynomial-fitting[55] 
-Asymmetric Least Squares[56] 
-B-splines[34] 
Alignment 
Correction of peak shift caused by 
instrumental factors 
-Changes of pH, temperature 








-Warping correlation optimized 
warping (COW) [60] 




Used for quantitative, objective or scored 
integrals of specific spectral peak 
dimensional 
Reduce the data 
-Equidistant binning of 0.04ppm 
-Non equidistant binning adaptive-
intelligent binning (Al-binning) 
-Gaussian binning 
-Adaptive binning with wavelet 
transform 
-Dynamic Adaptive binning 
Normalization[64] 
Make all samples comparable with each 
other 
-Dilution effects (especially for urine 
samples) 
Eliminate systematic errors 
Delete inter-sample variation 
-Probabilistic normalization (PQ) 
-Histogram Normalization 
-Group aggregation normalization 
(GAN) 
Scaling[30] 










Remove hetero scedasticy 










Table 4.  preprocessing of MS spectra (GC-MS) and (LC-MS) 
 Pre-processing Explain Solution 
Preprocessin





Mask the important components of 
the chromatographic data. 
One of the common ways of removing noise is 
based on a so-called “moving window” filter 
(Antoniou 1993; Mitra 1998) 
Data binning [68] 
Mass intensities are binned into 
Mass aligned vectors of uniform 
Length 
 
Make slices (default 0.1m/z) 
Assign intensity to each slice 
 For each scan. 
-Several methods available: 
- Bin (default) and Binlin, Binlinbase, Intlin 
Peak detection [68, 
69] 
-Identify all signals caused by true 
ions and avoid detection of false 
positives (i.e., noise, spikes) 
- Also aims to provide accurate 
quantitative information about ion 
concentrations 
-Detection in two directions by finding peaks 
independently in both m/z and retention time 
direction 
- The other strategy is slicing data to extract ion 
chromatograms (XIC), with each one covering a 
narrow m/z range, therefore avoiding the 
problem of searching for peaks in m/z direction. 
(XCMS) 
- For feature extraction is model fitting against 
the original raw signal 
Retention Time 
Alignment[70] 
Match peaks with similar retention 
times across 
Multiple samples, and use the groups 
of matched peaks for time alignment 
-AMDIS automatically finds peaks and 
deconvolutes the mass spectra of co-eluting 
compounds  
- A simple linear retention time shift could align 
peaks at only one of the time points, but not 
both.  
-The nonlinear alignment algorithm in XCMS 
properly aligns peaks over all times 
Missing values[71] 
Any peaks that failed to recognize  
 
-Using information from peak detection about 
where peaks begin and end, and aligned 
retention times for each sample 
Then integrate the raw LC/MS data to fill in 





It is necessary to remove the effect of 
the total amount from the analysis. 
Remove the unwanted systematic 
errors 
Bias in ion intensities between 
measurements, while 
Retaining the interesting biological 
variation 
Normalization by unit norm  
Normalization by median intensities, 
Normalization by the maximum likelihood 
method  
Normalization by a single or multiple internal or 
external standard compounds based on empirical 
rules, such as specific regions of retention time  
 
Scaling[73] 








  Chemometrics is one of an influential branch of 
chemistry and provides mathematical and 
statistical tools for data extraction and analysis of 
complex chemical and biological data. 
Multivariate analysis (MVA) is one of prominent 
subset of Chemometrics. This method of analysis 
is widely used in metabolomics studies that leads 
to reduces complexity and dimensionally of 
NMR/MS datasets and provides relevant 
 




biological information from the input analytical 
data obtained from instrument. These initial data 
consists of many different variables in a matrix. 
This matrix has column and rows, that columns 
are results of observations (variables: 
metabolites) and rows are objects. Any variable 
can be considered as a different dimension. 
Reduction of dimensionality can be done in one 
of two ways;  either unsupervised or supervised 
analysis[74, 75]. 
Unsupervised analysis 
   In unsupervised learning, input information 
(metabolite/peak data), are clustered into 
groups, revealing the overall structure on the 
data. One of the most applied methods is a 
principal component analysis (PCA). PCA is a 
method that reduces the dimension of data 
between variables in the dataset by application 
of covariance analysis. This technics is useful 
to identify hidden information within the data 
set by compressing of a data set and it is a 
linear combination of original data parameters. 
PCA utilizes a maximum of variables to the 
minimum of principal components (PCs). Each 
PC is orthogonal to the others. PCA can be 
visualized in two metrics, known Scores and 
Loadings. Score plot (T), is linear combinations 
of the original variables and reveals how the 
data is spread; each point expresses of a single 
spectrum, whereas loading plot/scatter plot (P) 
shows the effect (weight) of the individual X-
variables in the model. Each point depicts a 
different spectral intensity. Detections of 
outliers are another application of PCA [62]. 
Other unsupervised methods which have been 
used in metabolomics are k-means, 
HCA(Hierarchical cluster analysis ), STOCSY 
(statistical correlation spectroscopy), a hybrid 
of two methods of  STOCSY and  HCA that 
known as CLASSY (cluster analysis statistical 
spectroscopy)[76]. 
In table 5 briefly about each of them have been 
explained. Unsupervised analyzing methods have 
some limitations because of the character of 
unsupervised learning that cannot predict and 





Table 5. Other unsupervised methods 
unsupervised methods explain 
Hierarchical cluster 
analysis (HCA) 
-Make group based on 
similarity 
- Necessary choice of two 
input function 
K-means Clustering approach 




Extract of information from 
1D , 2D-NMR 
-Applied in drug 
metabolites 
Cluster analysis, statistical 
spectroscopy (CLASSY) 
-Better than STOCSY 
- Applied in hyphenated 
techniques  
-Is highly accurate 
 
Supervised Analysis 
   In supervised techniques the input information 
(metabolite/peak date), is paired with defined 
outputs e.g. disease or control (training data) and 
a model is built to classify the data. Some of 
statistical strategies are used for prediction of 
models, include, partial least square (PLS) which 
is a linear regression method; discriminant 
function analysis (DFA), Principal Component 
Regression (PCR),  partial least square 
discriminant analysis (PLS-DA) and OPLS 
method is modified form of the PLS method to 
help overcome the pitfalls. These techniques use a 
subset of the overall data (training data), to model 
the outcomes. The remaining data set is used to 
validate the predictive strength of the built model 
[78]. Validation is a very important step in 
evaluating a model for an independent Dataset. 
Several methods for validation of models exist. In 
a few years An Artificial neural network (ANN) 
method has been extensively used  as a non-linear 
data modeling method in metabolic studies and 
pathway analysis [79].  A relevant criterion for 
assessing the quality of fit models And determine 
the correct prediction of the Performance is 
defined under the curve receiver operating 
characteristic (ROC) [80]. The most common 
methods are cross-validation, double cross-
validation [81]. Many data in metabolic systems 








Complexity and environmental factors [81] . The 
linear methods are close to fail in such situations. 
Therefore Metabolites that are significant can be 
further analyzed using the receiver-operator  
Characteristic (ROC) curve. This is a plot of the 
degree of sensitivity (predicting a disease) versus 
specificity (predicting non-disease), and is used to 
identify the most discriminatory metabolites, 
based on a ROC score identify cutoff points for 
metabolites [82]. the Performance is defined 
under the curve receiver operating characteristic 
(ROC) [80]. The most common methods are 
cross-validation, double cross-validation [81]. 
Many data in metabolic systems display non-
linear dependencies because of biological  
Complexity and environmental factors [81] . 
The linear methods are close to fail in such 
situations.  
Therefore Metabolites that are significant can 
be further analyzed using the receiver-operator 
characteristic (ROC) curve. This is a plot of the 
degree of sensitivity (predicting a disease) 
versus specificity (predicting non-disease), and 
is used to identify the most discriminatory 
metabolites, based on a ROC score identify 
cutoff points for metabolites [82]. 
Common Database for Metabolomics 
    Metabolomics  like  other  “Omics”  sciences 
 dealing with complex and high throughput 
data, then Researcher to identify metabolites, 
assignment of compounds, exact mass, GC-EI 
spectrum, MS/MS spectrum comparison, 
identity of pathways Require access to a 
comprehensive database. We listed here the 
major open-access resources available (Table6) 
Application of Metabolomics 
     Recently, metabolomics has been used in 
many research fields, for example in the study 
of toxicology [83] responses to environmental 
stress [84], , nutrition [85], drug discovery [86]  
diagnosis of disease [87-94],identify 
biomarkers of disease and prognostic 
biomarkers [90] cancer [95-97], in natural 
product (plant metabolomics)  [98], and in 
traditional medicine [99-101]. Metabolomics 
allow the accurate prediction of disease, 
etiology and mechanisms[102, 103] Cancer is a 
complex disease state that changes the normal 
of healthy cells into tumor cells. Due to the 
cancer is associated with metabolic changes, 
therefore metabolomics studies can help in 
early stage detection and diagnosis of cancer 
and in evaluation of clinical trial. In this section 
we briefly describe the biomarkers identified in 
cancer diseases. identifed biomarkers kinds of 
cancers listed in the Table7. 
 
 
Table 6. Common database for metabolic study 
Database characteristics 
METLIN[104] The METLIN Database is a repository of metabolite information as well as tandem mass 




The database contains three kinds of data: 1) chemical data, 2) clinical data, and 3) 
molecular biology/biochemistry data. 
Many data fields are hyperlinked to other databases (KEGG, PubChem, MetaCyc, ChEBI, 
PDB, Swiss-Prot, and GenBank) and a variety of structure and pathway viewing applets. 
BiGG[106]  The BiGG database is a metabolic reconstruction of human metabolism designed for 
systems biology simulation and metabolic flux balance modeling. It is a comprehensive 
literature-based genome-scale metabolic  
SetupX[107] 
 
SetupX, developed by the Fiehn laboratory and is web-based. It displays GC-MS 
metabolomic data through its metabolic annotation database called BinBase. BinBase is a 
GC-TOF metabolomic database 
SYSTOMONAS[108] 
 
(SYSTems biology of pseudOMONAS) is a database for systems biology studies of 
Pseudomonas species. It contains transcriptomic, proteomic and metabolomic data as well 
as metabolic reconstructions of this pathogen.  
MetaboLights[109] MetaboLights is a database for metabolomics experiments. It is cross-species, cross-
technique and covers metabolite structures and their reference spectra as well as their 
biological roles, locations, concentrations and experimental data from metabolic 
experiments.  
 






MassBank is a mass spectral database of experimentally acquired high resolution MS 
spectra of metabolites. Maintained and supported by the JST-BIRD project, it offers 
various query methods for standard spectra obtained from Keio University, RIKEN PSC, 
and other Japanese research institutions. It is officially sanctioned by the Mass 
Spectrometry Society of Japan. The database has very detailed MS data and excellent 
spectral/structure searching utilities. More than 13,000 spectra of 1900 different 




The Golm Metabolome Database provides public access to GC/MS libraries which are 
stored as Mass Spectral (MS) and Retention Time Index (RI) Libraries (MSRI). These 
libraries of mass spectral and retention time indices can be used by the NIST/AMDIS 
software to identify metabolites according their spectral tags and RI's. The libraries are 
both searchable and downloadable and have been carefully collected under defined 
conditions on several types of GC/MS instruments (quadrupole and TOF). 
Fiehn GC-MS Database 
 
This database contains characteristics of compounds (name, structure, CAS ID, other links) 




The Birmingham Metabolite Library Nuclear Magnetic Resonance database is a freely 
available resource .This database includes both 2-D 1H J-resolved spectra and 1-D 1H 
spectra, recorded at 500 MHz using various water suppression methods and acquisition 
parameters, for solutions at pH values of 6.6, 7.0 and 7.4.  
MzCloud[113] 
 
MzCloud features a searchable collection of high resolution/accurate mass spectral trees 
using a new third generation spectra correlation algorithm. MzCloud tries to address the 
identification bottleneck by considering all mass spectrometricaly relevant aspects, looking 
at number of experimental and computational details and in some cases, allowing 
identification of unknowns even if they are not present in library. 
BMRB [114] 
 
The BioMagResBank (BMRB) is the central repository for experimental NMR spectral 
data, primarily for macromolecules. The BMRB also contains a recently established 
subsection for metabolite data. The current metabolomics database contains structures, 
structure viewing applets, nomenclature data, extensive 1D and 2D spectra peak lists (from 
1D, TOCSY, DEPT, HSQC experiments), raw spectra and FIDs for nearly 500 molecules.  
MMCD [115] 
 
The Madison Metabolomics Consortium Database (MMCD) is a database of chemicals. 
This database provides the chemical formula, names and synonyms, structure, physical and 
chemical properties, NMR and MS data on pure compounds under defined conditions, 
NMR chemical shifts determined by empirical and/or theoretical approaches, information 
on the presence of the metabolite in different biological species, and extensive links to 
images, references, and other public databases. 
 
Table7. Identified biomarkers by metabolomics studies 




Tissue GC-ToF-MS 51 metabolites were significantly different between 
borderline tumors and carcinomas 
Glycerol phosphate alpha, Lactic acid 
[116] 






GC/MS Taurine, lactate, choline, inositol, glycine, phosphocholine, 
proline, phenylalanine, alanine, threonine, valine and 
leucine 






Serum GC-MS  3-hydroxypropionic acid, pyruvic acid [119] 
Lung cancer Urine NMR Hippurate, trigonelline, ß-hydroxyisovalerate, α-
hydroxyisobutyrate, N-acetylglutamine and creatinine 
[122] 
Lung cancer Plasma NMR High concentration( lactate, pyruvate) 
Low concentration (citrate, Formate, acetate, glucose, 
[123] 
 




glutamine, alanine, tyrosine and Valine)  







Serum NMR Higher levels of acetate, N-acetylglycoproteins, 
Private, glutamine, a-ketoglutarate, glycerol, 
Tyrosine, 1-methylhistidine and phenylalanine, together 
with  
Lower levels of low-density lipoprotein, Isoleucine, Valine, 
acetoacetate, 











Tissue HR-MAS and 
solution NMR 
Lactate, mobile lipids (correlate with the degree of tumor 
necrosis 
 The ratio of (Phosphocholine/choline (correlates with 
malignancy of glioma) 
 
[128] 
Breast Cancer  HR-MAS Coline, phosphocholine/glycerophosphocholine (degree of 
tumor) 
 Glutamine, glutamate, glycine and taurine (in tumor type 
discrimination) 
[129] 
Breast Cancer Breast 
tissue 
HR-MAS High level (taurine, choline containing metabolites) [130] 
Breast Cancer Extract 
of 
tumor 
NMR In normal tissue (High level of glucose, Myo-inositol) 
In tumor tissue (phosphocholine, lactate, succinate) 
[131] 




Tissue HR-MAS Higher levels of lactate, amino acids, choline and lower 









14 potential salivary metabolites were identified. Eight 
biomarkers up-regulated in OSCC patients are compared 
with control and six down-regulated groups. 
Five salivary biomarkers (propionylcholine, N-Acetyl-L-






As seen in the table, levels of glucose, pyruvate, 
taurine , lactate have been increased and levels of 
phosphocholine, choline betaine and glycine have 
been decreased. Cancer cells request more energy 
that supplies it by high rate of glycolysis then 
going up lactic acid fermentation in the cytosol 
that it is known as the “Warburg” effect [135]. 
Proliferation of tumor in acidic environment 
elevates and in acidic media tumor cells invade to 
healthy cells.[136]. Therefore level of glucose has 
been decreased. [137, 138]. Glucose generates 
precursors of amino acids, lipids , and nucleotides 
[135]. Also Levels of fatty acids have been 
increased in early stage of cancer (specially breast 
cancer [139, 140]) and it is related to conversion 
of pyruvate to acetyl CoA.  Acetyl CoA can be 
consumed for de novo fatty acid synthesis [141].  
Reduced Level of Glycine has been observed in 
tumor cells because glycerin is a precursor for 
purine synthesis, and glycine has been consumed 
to produce sarcasm.  Levels of urinary Sarcosion 
had been increased in prostate cancer. [142, 143]. 
Sarcosine is produced by methyl transfer from 
SAMe(S-adenosyl-L-methionine) to glycine. 
The levels of Choline, phosphocholine, 
phosphatidylcholine, and glycerophospho-choline 
have been increased in brain, breast, prostate and 
liver cancers[96, 144] . Decreased levels of 
Lysophosphati-dylcholines (lysoPCs) have been 
observed in lung [145]and liver cancer [146]. 
while lysophosphatic acid has been reported as 
 




increased in ovarian cancer[147] (lysoPCs) are 
lipid intermediates that can used to form PCs or 
are the products of phospholipases acting on PCs. 
ratios of (glycerophosphocholine and 
phosphocholine)/creatine, myo-inositol/ scyllo-
inositol, choline/creatine and other ratios were 
demonstrated to correlate with the number of 
tumor cells, tumor cell proliferation[148]. 
Therefore in cancer cells, metabolites are 
associated with increased glycolysis, anaplerosis, 
and membrane choline metabolism. 
 
CONCLUSION 
    Metabolomics use  in a wide variety of 
disciplines, including  toxicology, systems 
biology, pharmacology, and medicine, especially 
in prognoses, diagnoses and therapy. Actually, 
diseases are perturbation in metabolic orders. 
Therefore,  measurement of metabolites in the 
healthy and disease state leads to a better 
understanding on the mechanism of the disease, 
finding  metabolic pathways involved in disease.  
In this review, we briefly explained about 
research strategies and analytical tools that use 
and chemometric approaches (MVA) and the 
most common databases and finally application of 
metabolomics in diagnosis of cancer diseases.  
 It is noticeable that metabolic studies are being 
applied to better understand metabolism of cancer 
cells, for diagnosis and prognosis  biomarkers. 
One of most limitations of metabolomics is that  
known biomakers  are still experimental and in 
the research phase, there are some challenges 
include identification of all the variables 
(unknown peaks)by improvement in analytical 
tools and chemometrics, validation studies for 
high population,  communion of clinical 
metabolomics data with the clinic, Detailed 
interpretation of clinical metabolomics data, and 
Following results of NMR and MS in the clinical.  
Due to metabolomics is the downstream  
approach and complimentary to the other omics 
approaches. The future of medical research within 
the field of cancer will use from information of 
systems biology particularly metabolomics to 
diagnosis biomarkers. 
Systems biology  approaches   will combine 
together until acquire detailed information about 
cancer pathways, therefore, will facilitate 
understanding about the complexity of cancer. 
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